Main Conference - Day 1 Keynote Sessions (May 15)
Main Conference - Day 1 Keynote Sessions (May 15)
- Thomas Vrucina - Deputy Head Liposome Technology, Polymun Scientific
- Aaron Cowley, PhD - Chief Scientific Officer, ReciBioPharm
- Frank Bennett, PhD - Executive Vice President and Chief Scientific Officer, Ionis Pharmaceuticals
- George Church, PhD - Professor of Genetics, Harvard Medical School
- Kyle Schneider, PhD - R&D Director, Vestaron
- Sarah DeVos, PhD - Director and Principal Scientist, Denali Therapeutics
Aldevron’s significantly expanded mRNA capabilities includes enhancements to drug product and drug substance manufacturing, as well as advanced analytical testing capabilities. At this luncheon, learn more about those advancements, and how Aldevron continues to expand its sequence-to-vial mRNA ecosystem.
- Todd Howren, PhD - Vice President RNA Client Services, Aldevron
- Daniel Samson, PhD - Vice President, Head Oligonucleotides, Bachem AG
- Sirat Sikka - Senior Scientist, Applications & Innovation, Thermo Fisher Scientific
- Chunping Xu, Ph.D - Director of Chemistry R&D, TriLink BioTechnologies
- Meg Brousseau, Ph.D. - Executive Director, Cardiovascular & Metabolic Diseases, Novartis
- Jacob Hyllested-Winge, M.D. - Project Vice President, Boston Global Development, Novo Nordisk
The discovery of the incretin system and the therapeutic benefits of glucagon-like peptide 1 (GLP-1) has prompted a wave of innovation, resulting in new classes of highly effective therapies for type 2 diabetes. Leveraging these therapies for their weight regulation effects has produced a fresh wave of innovation and the advent of novel, highly effective therapies for weight management. We will review emerging gut peptide-derived therapeutics for glucose and weight management, their mechanisms of action, and some unknowns and controversies.
- Kieren Mather, MD - Associate VP-Medical-Incretins and Diabetes Breakthroughs, Early Clinical Research, Eli Lilly and Company